V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214785 | 20081021 | 1.52 | 0 | null | 2017-07-29 | 2017-08-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100901294 |
| 20214786 | 20081022 | 1.72 | 0 | Palliative (P) | 2021-08-28 | 2021-09-02 | LANREOTIDE | 02 | N | LANREOTIDE | 100344211 |
| 20214788 | 20081024 | 1.67 | 116 | Palliative (P) | 2018-07-05 | 2018-07-10 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101481309 |
| 20214789 | 20081025 | 1.62 | 59 | null | 2018-04-07 | 2018-04-07 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100123714 |
| 20214790 | 20081026 | 1.64 | 46.1 | Palliative (P) | 2016-11-19 | 2016-11-26 | Imatinib 400mg | 02 | N | IMATINIB | 100511135 |
| 20214792 | 20081028 | 1.7 | 65.6 | Curative (C) | 2018-02-24 | 2018-02-26 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101407417 |
| 20214793 | 20081029 | null | null | Curative (C) | 2018-06-05 | 2018-06-15 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100041433 |
| 20214794 | 20081030 | null | null | Curative (C) | 2019-09-26 | 2019-10-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100717877 |
| 20214795 | 20081031 | 1.73 | 61.3 | Palliative (P) | 2018-01-07 | 2018-02-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101643614 |
| 20214797 | 20081032 | null | null | Palliative (P) | 2018-03-28 | 2018-03-28 | LANREOTIDE | 02 | N | LANREOTIDE | 101843833 |
| 20214799 | 20081034 | 1.58 | 81.3 | Curative (C) | 2017-07-03 | 2017-07-03 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101000117 |
| 20214800 | 20081035 | 1.86 | 80.8 | Palliative (P) | 2015-05-21 | 2015-06-06 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101032843 |
| 20214802 | 20081036 | 1.79 | 57.35 | Disease modification (D) | 2018-04-02 | 2018-04-03 | IMATINIB | 02 | N | IMATINIB | 101849047 |
| 20214803 | 20081037 | 1.71 | 97.65 | Curative (C) | 2016-09-14 | 2016-10-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101748652 |
| 20214804 | 20081038 | 1.66 | null | Palliative (P) | 2018-04-23 | 2018-05-01 | LANREOTIDE | null | N | LANREOTIDE | 100970358 |
| 20214805 | 20081039 | 1.75 | 58.8 | Palliative (P) | 2016-12-01 | 2016-12-07 | IMATINIB | N | N | IMATINIB | 100354503 |
| 20214806 | 20081040 | 1.74 | 0 | Curative (C) | 2019-07-28 | 2019-07-31 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100350957 |
| 20214807 | 20081041 | 0 | 86.6 | Palliative (P) | 2017-01-11 | 2017-01-11 | Imatinib 400mg | 02 | N | IMATINIB | 101556940 |
| 20214809 | 20081043 | 1.69 | 60 | Neo-adjuvant (N) | 2018-02-27 | 2018-03-01 | GO2 TRIAL | Y | N | TRIAL | 101870482 |
| 20214811 | 20081044 | 1.77 | 69.8 | Palliative (P) | 2020-01-21 | 2020-02-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101460566 |
| 20214812 | 20081045 | 1.69 | 66.2 | null | 2018-07-27 | 2018-07-27 | LANREOTIDE | 02 | null | LANREOTIDE | 101549213 |
| 20214813 | 20081046 | 1.76 | 82 | Palliative (P) | 2020-01-16 | 2020-01-16 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101416917 |
| 20214815 | 20081047 | 1.67 | 61 | Palliative (P) | 2018-07-17 | 2018-08-19 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100558366 |
| 20214816 | 20081048 | 1.7 | 71.2 | Curative (C) | 2017-06-10 | 2017-06-10 | Fluorouracil+Mitomycin+RT (Bladder) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100497187 |
| 20214819 | 20081050 | 1.49 | 58.1 | Palliative (P) | 2018-12-27 | 2019-01-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | TRIAL | 100479952 |
| 20214820 | 20081051 | 1.59 | 100 | Curative (C) | 2018-09-08 | 2018-09-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101487856 |
| 20214821 | 20081052 | null | 103.25 | null | 2019-08-04 | 2019-08-12 | LANREOTIDE | 99 | null | LANREOTIDE | 100808877 |
| 20214822 | 20081053 | 1.78 | 59 | Curative (C) | null | 2017-10-18 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101704048 |
| 20214823 | 20081054 | 1.65 | 64 | Disease modification (D) | 2018-11-06 | 2018-11-20 | Cape+Cisplatin+Trastuzumab Main | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100184401 |
| 20214824 | 20081055 | 1.7 | 114 | Neo-adjuvant (N) | 2018-03-21 | 2018-03-21 | Trial Unspecified | Y | N | TRIAL | 101510025 |
| 20214825 | 20081056 | 1.69 | 67.4 | Curative (C) | 2018-06-23 | 2018-07-07 | FLUOROURACIL + MITOMYCIN + RT | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 100335688 |
| 20214826 | 20081057 | 1.72 | 73.7 | Neo-adjuvant (N) | 2018-04-22 | 2018-04-22 | HCX | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100918669 |
| 20214828 | 20081059 | 1.69 | 68 | Curative (C) | 2019-12-22 | 2020-01-22 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100269835 |
| 20214829 | 20081060 | 1.65 | 78.4 | Curative (C) | 2017-06-12 | 2017-06-12 | HCX | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101580702 |
| 20214830 | 20081061 | 1.75 | 0 | Curative (C) | 2019-07-29 | 2019-08-13 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100315596 |
| 20214831 | 20081062 | 1.7 | 74 | Palliative (P) | 2018-05-26 | 2018-06-02 | LANREOTIDE | 02 | N | LANREOTIDE | 100607024 |
| 20214833 | 20081063 | 1.85 | 0 | Disease modification (D) | 2017-08-08 | 2017-08-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100260972 |
| 20214834 | 20081064 | 1.76 | 59.8 | Curative (C) | 2017-12-14 | 2018-01-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | Y | FLUOROURACIL + MITOMYCIN + RT | 100900742 |
| 20214835 | 20081065 | 1.57 | 74 | null | 2018-04-08 | 2018-04-08 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101479784 |
| 20214836 | 20081066 | 1.58 | 63.1 | null | 2019-10-15 | 2019-10-29 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101491028 |
| 20214838 | 20081067 | 1.71 | 58.9 | Palliative (P) | 2016-11-25 | 2016-11-25 | Trial Unspecified | 01 | Y | TRIAL | 101152518 |
| 20214839 | 20081068 | 1.73 | 91 | Palliative (P) | 2016-09-17 | 2016-10-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100794594 |
| 20214840 | 20081069 | 1.72 | 65.25 | Curative (C) | 2015-10-09 | 2015-10-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | N | FLUOROURACIL + MITOMYCIN + RT | 100191706 |
| 20214841 | 20081070 | 1.56 | 70.2 | Palliative (P) | 2016-09-28 | 2016-10-19 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100303403 |
| 20214842 | 20081071 | 1.74 | 77.9 | Curative (C) | 2018-02-09 | 2018-02-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101684077 |
| 20214843 | 20081072 | 1.8 | 80.4 | Curative (C) | null | 2014-06-14 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100155282 |
| 20214844 | 20081073 | 1.76 | 55.5 | Curative (C) | 2018-10-28 | 2018-10-28 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101295846 |
| 20214847 | 20081076 | 1.7 | 58.9 | Palliative (P) | 2018-12-23 | 2019-01-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101719580 |
| 20214848 | 20081077 | 1.76 | 56.3 | Curative (C) | 2018-11-29 | 2018-12-02 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100413053 |
| 20214849 | 20081078 | 1.48 | 57.35 | Palliative (P) | 2018-05-23 | 2018-05-23 | GO2 TRIAL | Y | N | TRIAL | 100899695 |